The Centers for Disease Control and Prevention (CDC) today reported two more variant influenza cases, one in Ohio and the other in Pennsylvania, in people who had contact with pigs.

Both patients are adults, recovered after hospitalization, and had underlying health conditions, the CDC said in its weekly influenza report.

Cases involve 2 different strains

The patient from Ohio had a variant H1N1 (H1N1v) infection and got sick after exposure to pigs at an agricultural event. Meanwhile, Pennsylvania's patient had a variant H1N2 (H1N2v) infection and had occupational exposure to swine.

So far 7 variant flu cases have been reported during the 2024-25 flu season in the United States, 4 from H1N2v, 2 from H3N2v, and 1 from H1N1v.

No symptoms were reported in the patients' contacts, and no related human-to-human cases have been identified.

Sporadic human infections with swine flu occur in the United States and other countries, most often in people who have contact with pigs or their environments. Many of the cases in the United States occur during the summer months, when agricultural fairs take place.

High-dose (HD) and adjuvanted influenza vaccines offered the best protection for people aged 65 years and older against symptoms and hospitalization during the 2022-23 flu season, concludes a real-world study published this week in Clinical Infectious Diseases.

High-dose flu vaccines contain four times the standard dose (SD), while adjuvanted vaccines contain an extra immune-boosting ingredient. In 2022, the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommended high-dose, adjuvanted, or recombinant (cell-based) vaccines over SD vaccines for older adults, who are at elevated risk for severe disease and flu-related hospitalization and death.

Kaiser Permanente Southern California researchers retrospectively assessed the comparative vaccine effectiveness (cVE) of HD, adjuvanted, and SD cell-based flu vaccines versus SD egg-based vaccines. 

Participants were 495,119 adults with a median age of 73 years who received a flu vaccine dose from August through December 2022 and were followed up to May 2023. Of all participants, 54.9% were women and 46.3% were White.

"Overall, influenza vaccine effectiveness (VE) has remained low (<50% between 2014 and 2022), particularly in seasons of mismatch between the vaccine and circulating strains," the study authors wrote. "To improve vaccine platforms and production, high-dose (HD), adjuvanted, recombinant, and standard-dose (SD) cell-based vaccines became available in addition to egg-based SD vaccines."

Adjuvanted vaccines most effective

In total, 74.8% of participants received high-dose flu vaccines, and the remainder received SD egg-based (13.9%), SD cell-based (6.5%), or adjuvanted (4.7%) vaccines.

The University of Colorado (UC) School of Medicine announced yesterday that it's been awarded $5 million from the US Department of Defense (DoD) to collect and study data on antibiotic-resistant wounds linked to the war in Ukraine.

Wound infections caused by multidrug-resistant organisms have substantially increased in Ukraine since Russian forces invaded the country in 2022, complicating treatment for frontline providers. Yet no systematic data for wound infections exist in Ukraine. Through the project, called the Antimicrobial Resistance Research to Improve Outcomes of Traumatic Wounds study (ARROW) study, UC researchers will work with researchers in Ukraine to create infrastructure for collecting such data.

Wound infection a 'top concern' for US military

The project aims to enroll up to 1,000 patients and collect data on injury and wound characteristics, molecular testing, and clinical outcomes, with researchers in Ukraine collecting specimens at three frontline hospitals and two referral centers over the next 2 years. UC researchers say these data will help providers in Ukraine during the current conflict and enable clinical trials to test solutions that help prevent and treat wound infections in future conflicts.

"Wound infection is consistently identified as a top concern in Ukraine and the U.S. military, which is why we are moving forward on this project first," Adit Ginde, MD, MPH, a professor of emergency medicine at UC and principal investigator on the project, said in a UC press release. "The first step is actually describing the problem in a more systematic way and then quickly pivot[ing] to clinical trials."

Roman Fishchuk, MD, a researcher at Central City Clinical Hospital of Ivano-Frankivsk in western Ukraine, will lead the in-country data collection effort.

“I'm grateful to our colleagues at the University of Colorado for being brave, working with us, and being so proactive," Fishchuk said. "This partnership is inspiring and helps us do our job and think about research in new ways."

Analysis of data from a phase 3 clinical trial provides some clues as to how a microbiota-based treatment helps prevent recurrent Clostridioides difficile (rCDI) infection, researchers reported yesterday in the Journal of Infectious Diseases.

For the study, researchers analyzed stool samples from participants in PUNCH CD3, a randomized clinical trial that found the fecal microbiota-based live biotherapeutic Rebyota (RBL) was clinically superior to placebo in preventing rCDI. The researchers wanted to investigate the extent to which RBL restores the balance of bacteria and bile acid (BA) in the gut microbiome following antibiotic therapy, which is typically the first line of treatment for rCDI patients but often causes further gut microbiome disruption and increases the risk of future recurrence.

RBL linked to microbiota, BA changes    

Stool samples were collected from participants who received a dose of RBL or placebo at baseline and 1, 4, and 8 weeks after treatment. Sequencing of those samples revealed that, before administration, Gammaproteobacteria and Bacilli dominated the microbiota community, and primary BAs were more prevalent than secondary BAs in trial participants. These characteristics are associated with reduced resistance to C difficile colonization, the study authors note. 

"Thus, trial participants were dysbiotic before study treatment in ways that could enable CDI recurrence," they wrote.

In participants who responded to treatment with RBL or placebo, clinical success after administration correlated with shifts to predominantly Bacteroidia and Clostridia, a significant increase in the Microbiome Health Index, and a shift from primary to secondary BAs. But several microbiota and BA changes were more extensive in RBL-treated responders than in placebo-treated responders, and microbiota changes correlated with BA changes.

"Overall, the microbiome and BA analyses herein support a model in which Bacteroidia restoration, decreased Gammaproteobacteria levels, and the increased metabolism of primary to secondary BAs were potential drivers of RBL clinical efficacy," the authors concluded.

RBL was approved by the US Food and Drug Administration for the prevention of rCDI in 2022 based on data from PUNCH CD3 and other clinical trials.